NYSE:ALT - Altimmune Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.91 -0.19 (-6.13 %) (As of 01/18/2019 04:00 PM ET)Previous Close$3.10Today's Range$2.87 - $3.0952-Week Range$1.70 - $58.50Volume260,392 shsAverage Volume485,807 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland. Receive ALT News and Ratings via Email Sign-up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSE:ALT Previous Symbol CUSIPN/A Webwww.altimmune.com PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares8,755,000Market Cap$0.00 OptionableOptionable Altimmune (NYSE:ALT) Frequently Asked Questions What is Altimmune's stock symbol? Altimmune trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALT." How were Altimmune's earnings last quarter? Altimmune, Inc. (NYSE:ALT) issued its quarterly earnings results on Tuesday, November, 13th. The company reported ($1.73) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($3.60) by $1.87. The company had revenue of $2.63 million for the quarter, compared to analyst estimates of $2.52 million. View Altimmune's Earnings History. When is Altimmune's next earnings date? Altimmune is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for Altimmune. What is the consensus analysts' recommendation for Altimmune? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Altimmune. Has Altimmune been receiving favorable news coverage? Media headlines about ALT stock have trended somewhat negative this week, according to InfoTrie. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Altimmune earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Altimmune's key competitors? Some companies that are related to Altimmune include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE). Who are Altimmune's key executives? Altimmune's management team includes the folowing people: Mr. William J. Enright, Pres, CEO & Director (Age 55)Dr. M. Scot Roberts Ph.D., Chief Scientific Officer (Age 59)Dr. Sybil Tasker, Chief Medical Officer (Age 55)Mr. Will Brown, Acting CFO & Principal Accounting Officer (Age 36)Mr. Bertrand Georges Ph.D., Chief Technology Officer How do I buy shares of Altimmune? Shares of ALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Altimmune's stock price today? One share of ALT stock can currently be purchased for approximately $2.91. What is Altimmune's official website? The official website for Altimmune is http://www.altimmune.com. MarketBeat Community Rating for Altimmune (NYSE ALT)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 50 (Vote Outperform)Underperform Votes: 62 (Vote Underperform)Total Votes: 112MarketBeat's community ratings are surveys of what our community members think about Altimmune and other stocks. Vote "Outperform" if you believe ALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/18/2019 by MarketBeat.com StaffFeatured Article: What is a balanced fund?